"Oltov\u00E1, Alexandra" . . "Elsevier" . "Budapest, Hungary" . "1"^^ . "Kugl\u00EDk, Petr" . . "2007-08-29+02:00"^^ . "10"^^ . . . "Gre\u0161likov\u00E1, Henrieta" . "14110" . "Vidl\u00E1kov\u00E1, Petra" . . . "Blood Reviews" . . . "[9FFF5914E0F5]" . . "P(LC06027)" . . . . . . "Prognostic impact of 1q21 amplification in patients with multiple myeloma treated by velcade, thalidomide and any conventional chemotherapy"@en . . "Vranov\u00E1, Vladim\u00EDra" . "Prognostic impact of 1q21 amplification in patients with multiple myeloma treated by velcade, thalidomide and any conventional chemotherapy" . "445063" . "Zaoralov\u00E1, Romana" . "Prognostic impact of 1q21 amplification in patients with multiple myeloma treated by velcade, thalidomide and any conventional chemotherapy"@en . "Neuveden" . "Introduction Amplification of chromosome band 1q21 as well as increased expression of CKS1B gene in this area is a frequently mentioned prognostic factor for patients with multiple myeloma (MM). This study was aimed at comparison of prognostic impact of 1q21 gain in three selected groups of patients with diagnosed MM based on treatment regiment. Materials and Methods Plasma cells were identified by cytoplasmic light chain fluorescence in situ hybridisation (cIg-FISH), 1q21 amplification (Amp1q21) utilizing the 1q21/1p36 DNA probe. Amp1q21 was taken such as detection of one or more additional signals of 1q21. Cut-off level for Amp1q21 was established to 20% of total amount of cells with additional signals detected. Patients with Amp1q21 and patients lacking Amp1q21 of each group were statistically correlated with clinical parameters. Up to date we have carried out analysis of 66 (n=66) patients."@en . "Prognostic impact of 1q21 amplification in patients with multiple myeloma treated by velcade, thalidomide and any conventional chemotherapy" . . . "RIV/00216224:14110/07:00022792" . "RIV/00216224:14110/07:00022792!RIV10-MSM-14110___" . "Smejkalov\u00E1, Jana" . . . . . . "multiple myeloma; 1q21 amplification; velcade; thalidomide; fluorescence in situ hybridisation"@en . . "0268-960X" . "Filkov\u00E1, Hana" . "H\u00E1jek, Roman" . . "Introduction Amplification of chromosome band 1q21 as well as increased expression of CKS1B gene in this area is a frequently mentioned prognostic factor for patients with multiple myeloma (MM). This study was aimed at comparison of prognostic impact of 1q21 gain in three selected groups of patients with diagnosed MM based on treatment regiment. Materials and Methods Plasma cells were identified by cytoplasmic light chain fluorescence in situ hybridisation (cIg-FISH), 1q21 amplification (Amp1q21) utilizing the 1q21/1p36 DNA probe. Amp1q21 was taken such as detection of one or more additional signals of 1q21. Cut-off level for Amp1q21 was established to 20% of total amount of cells with additional signals detected. Patients with Amp1q21 and patients lacking Amp1q21 of each group were statistically correlated with clinical parameters. Up to date we have carried out analysis of 66 (n=66) patients." . . . "N\u011Bmec, Pavel" . "10"^^ . .